Study details
Enrolling now
A Single-Arm Phase II Trial of Aspirin to Prevent Blood Clots in Patients with Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
NCT IDNCT06866964ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
35
Study length
about 5.4 years
Ages
18–70
Locations
3 sites in NC, WI
About this study
This trial is testing whether low-dose aspirin can help prevent blood clots (VTE) in adults with advanced germ cell tumors who are receiving chemotherapy. The goal is to compare the 6-month VTE-free rate of participants taking aspirin to historical data from patients without aspirin.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Low-dose ASA
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Overall Survival (OS), Relapse-Free Survival (RFS)
Body systems
Oncology